ERBB2 and neoplasm: In accordance with the data reported in the literature [20, 21, 24], we found a strong association between the HER2-low status in recurrent tumours and HR expression in matched primary tumours, with a high proportion of HR-positive HER2-negative tumours that relapsed as HER2-low tumours.